JP2012507535A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507535A5
JP2012507535A5 JP2011534624A JP2011534624A JP2012507535A5 JP 2012507535 A5 JP2012507535 A5 JP 2012507535A5 JP 2011534624 A JP2011534624 A JP 2011534624A JP 2011534624 A JP2011534624 A JP 2011534624A JP 2012507535 A5 JP2012507535 A5 JP 2012507535A5
Authority
JP
Japan
Prior art keywords
acceptable salt
pharmaceutically acceptable
hydrogen
fluoro
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011534624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507535A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/061573 external-priority patent/WO2010062507A1/en
Publication of JP2012507535A publication Critical patent/JP2012507535A/ja
Publication of JP2012507535A5 publication Critical patent/JP2012507535A5/ja
Pending legal-status Critical Current

Links

JP2011534624A 2008-11-03 2009-10-22 二置換フタラジンヘッジホッグ経路アンタゴニスト Pending JP2012507535A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11070308P 2008-11-03 2008-11-03
US61/110,703 2008-11-03
PCT/US2009/061573 WO2010062507A1 (en) 2008-11-03 2009-10-22 Disubstituted phthalazine hedgehog pathway antagonists

Publications (2)

Publication Number Publication Date
JP2012507535A JP2012507535A (ja) 2012-03-29
JP2012507535A5 true JP2012507535A5 (en:Method) 2012-12-13

Family

ID=41566219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534624A Pending JP2012507535A (ja) 2008-11-03 2009-10-22 二置換フタラジンヘッジホッグ経路アンタゴニスト

Country Status (29)

Country Link
US (1) US8404687B2 (en:Method)
EP (1) EP2364185B1 (en:Method)
JP (1) JP2012507535A (en:Method)
KR (1) KR101335746B1 (en:Method)
CN (1) CN102202737B (en:Method)
AU (1) AU2009320251C1 (en:Method)
BR (1) BRPI0921437A2 (en:Method)
CA (1) CA2742539C (en:Method)
CL (1) CL2011000979A1 (en:Method)
CO (1) CO6382123A2 (en:Method)
CR (1) CR20110202A (en:Method)
CY (1) CY1114023T1 (en:Method)
DK (1) DK2364185T3 (en:Method)
EA (1) EA018931B1 (en:Method)
EC (1) ECSP11011021A (en:Method)
ES (1) ES2418479T3 (en:Method)
HR (1) HRP20130527T1 (en:Method)
IL (1) IL211841A0 (en:Method)
MA (1) MA32726B1 (en:Method)
MX (1) MX2011004683A (en:Method)
NZ (1) NZ591945A (en:Method)
PE (1) PE20110433A1 (en:Method)
PL (1) PL2364185T3 (en:Method)
PT (1) PT2364185E (en:Method)
SI (1) SI2364185T1 (en:Method)
TN (1) TN2011000166A1 (en:Method)
UA (1) UA102115C2 (en:Method)
WO (1) WO2010062507A1 (en:Method)
ZA (1) ZA201102448B (en:Method)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ579402A (en) * 2007-03-15 2012-03-30 Novartis Ag Organic compounds for diagnosis and treatment of pathologies relating to the Hedgehog pathway
MX2010011948A (es) 2008-04-29 2010-12-14 Lilly Co Eli Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AU2009314288B2 (en) 2008-11-17 2013-05-02 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
CA2743483C (en) 2008-11-17 2014-03-11 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
EP4229828A4 (en) 2020-10-13 2024-08-28 Endeavor Biomedicines, Inc. METHODS OF TREATMENT OF FIBROSIS
US20240124451A1 (en) * 2022-09-23 2024-04-18 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
SI0876366T1 (en) * 1996-01-15 2001-12-31 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
ATE480521T1 (de) * 1996-10-01 2010-09-15 Kyowa Hakko Kirin Co Ltd Stickstoff enthaltende heterocyclische verbindungen
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
EP1067939B1 (en) 1998-04-09 2015-09-16 The Johns Hopkins University Use of steroidal alkaloid derivatives as inhibitors of hedgehog protein signaling pathways
ATE283700T1 (de) 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
JP2005529876A (ja) 2002-04-22 2005-10-06 ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン Hedgehogシグナル伝達経路の調節因子、それに関連する組成物および使用
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
US8338591B2 (en) 2004-05-08 2012-12-25 Novartis International Pharmaceutical Ltd. 3-aryl-5,6-disubstituted pyridazines
KR20210090744A (ko) * 2004-09-02 2021-07-20 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
NZ579402A (en) * 2007-03-15 2012-03-30 Novartis Ag Organic compounds for diagnosis and treatment of pathologies relating to the Hedgehog pathway
CA2690378A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009035568A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
MX2010011948A (es) 2008-04-29 2010-12-14 Lilly Co Eli Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2743483C (en) 2008-11-17 2014-03-11 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
AU2009314288B2 (en) 2008-11-17 2013-05-02 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Similar Documents

Publication Publication Date Title
JP2012507535A5 (en:Method)
JP2012530705A5 (en:Method)
JP2012509263A5 (en:Method)
JP2011529054A5 (en:Method)
JP2010523692A5 (en:Method)
JP2013537203A5 (en:Method)
JP2014515013A5 (en:Method)
JP2016503786A5 (en:Method)
JP2011527666A5 (en:Method)
JP2011519854A5 (en:Method)
JP2015512931A5 (en:Method)
JP2011500550A5 (en:Method)
JP2011528658A5 (en:Method)
JP2012533546A5 (en:Method)
JP2009545527A5 (en:Method)
JP2010513478A5 (en:Method)
JP2009515988A5 (en:Method)
JP2013543896A5 (en:Method)
JP2006526031A5 (en:Method)
JP2009502743A5 (en:Method)
JP2013523733A5 (en:Method)
JP2011527332A5 (en:Method)
JP2015531774A5 (en:Method)
JP2013506674A5 (en:Method)
JP2012509265A5 (en:Method)